IRB #

STUDY00019560

Title

A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT® FOR ATOPIC DERMATITIS (R668-AD-1762)

Principal Investigator

Eric Simpson

Study Purpose

To assess the long-term effectiveness and safety of adults who are currently taking DUPIXENT for AD.

Medical Condition(s)

eczema , atopic dermatitis (AD)

Eligibility Criteria

A patient must meet all of the following criteria to be eligible for inclusion in the study:
1. Male or female, 12 years or older at the baseline visit
2. Initiating treatment with DUPIXENT for AD according to the country-specific
prescribing information
3. Willing and able to comply with study-related activities
4. Able to understand and complete study-related questionnaires
5. Provide signed informed consent

Please note that DUPIXENT will not be supplied in the study.

Healthy Volunteers Needed

No

Placebo Chance

Duration of Participation

60 months

Minors Included

Yes

Contact

Call our Dermatology clinical trials recruiter at 503-418-9386 or email dermtrials@ohsu.edu

Sponsor

Regeneron Pharmaceuticals, Inc.

Recruitment End

12/31/2021

Compensation Provided

Yes

Compensation

You will be paid $25.00 for your time to complete monthly questionnaires. If you complete questionnaires every month for the full 60 months you will be compensated $1050.


Go Back